Lysteda TV ads make some networks squeamish

Share this article:
Lysteda TV ads make some networks squeamish
Lysteda TV ads make some networks squeamish
Ferring Pharmaceuticals is launching its first branded TV ad with spots for its Lysteda treatment for heavy menstrual bleeding.

The ad's up-front discussion of the condition, featuring the tagline “Help for heavy periods,” put network execs off,  with some initially refusing to air it. The spot depicts women walking serenely through falling rose petals to visualize the product's benefits.

“Periods are a natural part of a woman's life,” says the voiceover. “But what if your periods are unusually heavy? That may be a medical condition called heavy monthly bleeding.” Up to 22 million American women suffer from heavy monthly bleeding, according to Ferring.

The ad casts Lysteda as an alternative to hormones or surgery, “the first and only pill to help reduce heavy monthly bleeding by about one third.” It's part of an integrated campaign including print and branded and unbranded online elements.

The ads were spearheaded by Ferring VP US marketing Bill Garbarini and product manager Cicek Tilley. Creative concepts for the spots were developed by Integrated Media Solutions and DePirro/Garrone. The campaign is being executed by Integrated Communications Corp., Westfield Group Medical Communications and Kovak-Likely Communications.

Lysteda (tranexamic acid) won FDA approval as the first non-hormonal product for treatment of heavy menstrual bleeding in November, 2009, and Ferring acquired the drug from Xanodyne Pharmaceuticals in May.
 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...